EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A New Fragment‐Based Pharmacophore Virtual Screening Workflow Identifies Potent Inhibitors of SARS ‐ CoV ‐2 NSP13 Helicase

Jordi Doijen iD, Jiexiong Xie, Simone Marsili, Trpta Bains, Mandeep Kaur Mann iD, Pravien Abeywickrema, Nick Van den Broeck iD, Christian Permann, Thierry Langer iD, Gökhan Ibis, Charles-Alexandre Mattelaer iD, Jeremy Harvey iD und 9 weitere

Journal of Computational Chemistry · 2025

DOI: 10.1002/jcc.70201 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Computational Chemistry, 2025. Verfasst von Jordi Doijen und 20 weiteren Autor:innen. Beteiligte Einrichtung: Johnson & Johnson, Beerse, Belgium. Hauptthemen laut MEDLINE: SARS-CoV-2, Antiviral Agents, Viral Nonstructural Proteins, RNA Helicases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vlaams Agentschap Innoveren & Ondernemen (VLAIO), Federal funds from the Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA), Corona Accelerated R&D in Europe (CARE).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Herein we report the in silico discovery of 13 novel micromolar potent inhibitors of the SARS‐CoV‐2 NSP13 helicase validated in cellular antiviral and biophysical ThermoFluor assays. The compounds, discovered using a novel fragment‐based pharmacophore virtual screening workflow named FragmentScout, enable the advancement of novel antiviral agents. FragmentScout uses publicly accessible structural data of the SARS‐CoV‐2 NSP13 helicase, which was previously generated at the Diamond LightSource by XChem high‐throughput crystallographic fragment screening. The workflow generates a joint pharmacophore query for each binding site, thereby aggregating the pharmacophore feature information present in each experimental fragment pose. The joint pharmacophore query is then used to search 3D conformational databases using the Inte:ligand LigandScout XT software. The FragmentScout in silico workflow offers a novel tool for identifying micromolar hits from millimolar fragments in fragment‐based lead discovery. It is anticipated that this workflow will enhance systematic data mining of the growing collection of XChem datasets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Antiviral AgentsViral Nonstructural ProteinsRNA HelicasesEnzyme InhibitorsHumansDrug Evaluation, PreclinicalLigandsWorkflowBinding SitesPharmacophoreMethyltransferases

Stichwörter der Autor:innen

FragmentScoutSARS‐CoV‐2 NSP13 helicasebroad‐spectrum antiviralfragment‐basedvirtual screening

Substanzen

Antiviral AgentsViral Nonstructural ProteinsRNA HelicasesNsp13 protein, SARS-CoVLigandsEnzyme InhibitorsMethyltransferases

Autor:innen und Institutionen

  • Johnson & Johnson, Beerse, Belgium.
  • Johnson & Johnson, Toledo, Spain.
  • Johnson & Johnson, Spring House, Pennsylvania, USA.
  • Charles River Laboratories, Beerse, Belgium.
  • Department of Pharmaceutical Sciences, University of Vienna, Vienna, Austria.
  • Inte:Ligand Software-Entwicklungs Und Consulting GmbH, Vienna, Austria.

ORCID-Profile: Jordi Doijen, Mandeep Kaur Mann, Nick Van den Broeck, Thierry Langer, Charles-Alexandre Mattelaer, Jeremy Harvey, Ellen Van Damme, Marnix Van Loock

Förderung

  • Vlaams Agentschap Innoveren & Ondernemen (VLAIO)
  • Federal funds from the Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA)
  • Corona Accelerated R&D in Europe (CARE)
  • Innovative Medicines Initiative 2 Joint Undertaking (JU). The JU receives support from the European Union's Horizon 2020 research and innovation program EFPIA,…
  • Agentschap Innoveren en Ondernemen
  • Biomedical Advanced Research and Development Authority

Zitieren

APA

Doijen, J., Xie, J., Marsili, S., Bains, T., Mann, M. K., Abeywickrema, P., Van den Broeck, N., Permann, C., Langer, T., Ibis, G., Mattelaer, C. A., Harvey, J., van Raalte, S., Fino, R., Pande, V., Peeters, D., Patrick, A., Van Damme, E., van Vlijmen, H., …, & Jacoby, E. (2025). A New Fragment‐Based Pharmacophore Virtual Screening Workflow Identifies Potent Inhibitors of SARS ‐ CoV ‐2 NSP13 Helicase. Journal of Computational Chemistry. https://doi.org/10.1002/jcc.70201

Vancouver

Doijen J, Xie J, Marsili S, Bains T, Mann MK, Abeywickrema P, et al. A New Fragment‐Based Pharmacophore Virtual Screening Workflow Identifies Potent Inhibitors of SARS ‐ CoV ‐2 NSP13 Helicase. Journal of Computational Chemistry. 2025. doi:10.1002/jcc.70201

BibTeX
@article{Doijen2025,
  author = {Doijen, Jordi and Xie, Jiexiong and Marsili, Simone and Bains, Trpta and Mann, Mandeep Kaur and Abeywickrema, Pravien and Van den Broeck, Nick and Permann, Christian and Langer, Thierry and Ibis, Gökhan and Mattelaer, Charles-Alexandre and Harvey, Jeremy and van Raalte, Sebastiaan and Fino, Roberto and Pande, Vineet and Peeters, Danielle and Patrick, Aaron and Van Damme, Ellen and van Vlijmen, Herman and Van Loock, Marnix and Jacoby, Edgar},
  title = {A New Fragment‐Based Pharmacophore Virtual Screening Workflow Identifies Potent Inhibitors of SARS ‐ CoV ‐2 NSP13 Helicase},
  journal = {Journal of Computational Chemistry},
  year = {2025},
  doi = {10.1002/jcc.70201}
}
Kostenlos starten →